{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:49:50Z","timestamp":1769086190016,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rdc.2021.07.012","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:15:23Z","timestamp":1630534523000},"page":"643-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacosurveillance in Juvenile Idiopathic Arthritis"],"prefix":"10.1016","volume":"47","author":[{"given":"Natalie J.","family":"Shiff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rdc.2021.07.012_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/bcp.12406","article-title":"The development and assessment of biological treatments for children","volume":"79","author":"Smith","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.012_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.012_bib3","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.07.012_bib4","unstructured":"World Health Organization. Quality Assurance and Safety of Medicines Team. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action. Geneva (Switzerland); 2002. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/67378. Accessed February 26, 2021."},{"issue":"12","key":"10.1016\/j.rdc.2021.07.012_bib7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/art.41043","article-title":"Toward accelerated authorization and access to new medicines for juvenile idiopathic arthritis","volume":"71","author":"Schanberg","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.012_bib8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/archdischild-2017-312994","article-title":"Extrapolation or controlled trials in paediatrics: the current dilemma","volume":"102","author":"Ruperto","year":"2017","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.rdc.2021.07.012_bib9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/archdischild-2016-312259","article-title":"Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases","volume":"102","author":"Stefanska","year":"2017","journal-title":"Arch Dis Child"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.012_bib10","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/art.27670","article-title":"Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.012_bib11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.rdc.2021.07.012_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.012_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/2229-3485.71852","article-title":"Phase IV of drug development","volume":"1","author":"Survana","year":"2010","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.rdc.2021.07.012_bib14","doi-asserted-by":"crossref","first-page":"e010643","DOI":"10.1136\/bmjopen-2015-010643","article-title":"Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry","volume":"6","author":"Zhang","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.012_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/21556660.2019.1566137","article-title":"Healthcare professionals\u2019 pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates","volume":"8","author":"Guner","year":"2019","journal-title":"J\u00a0Drug Assess"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.012_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance: the next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.012_bib17","first-page":"340","article-title":"Big data and pharmacovigilance: data mining for adverse drug events and interactions","volume":"43","author":"Ventola","year":"2018","journal-title":"P\u00a0T"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.012_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40264-018-0766-8","article-title":"Towards drug safety surveillance and pharmacovigilance: current progress in detecting medication and adverse drug events from electronic health records","volume":"42","author":"Liu","year":"2019","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.012_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cpt.320","article-title":"The FDA\u2019s sentinel initiative: a comprehensive approach to medical product surveillance","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rdc.2021.07.012_bib20","author":"Halevi"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.012_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1556984520902783","article-title":"Advanced data analytics for clinical research part i: what are the tools\u202f?","volume":"15","author":"Zhou","year":"2020","journal-title":"Innovations"},{"issue":"S10","key":"10.1016\/j.rdc.2021.07.012_bib22","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1002\/jcph.1141","article-title":"Identifying the \u201cblip on the radar screen\u201d: leveraging big data in defining drug safety and efficacy in pediatric practice","volume":"58","author":"Christensen","year":"2018","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.012_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.semradonc.2019.05.010","article-title":"The evolving use of electronic health records (EHR) for research","volume":"29","author":"Kim","year":"2019","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.rdc.2021.07.012_bib25","series-title":"Registries for evaluating patient outcomes: a user\u2019s guide","first-page":"18","year":"2020"},{"key":"10.1016\/j.rdc.2021.07.012_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch National Register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.012_bib27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.athoracsur.2017.06.077","article-title":"Risk aversion and public reporting. Part 1: observations from cardiac surgery and interventional cardiology","volume":"104","author":"Shahian","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.012_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/acr2.11091","article-title":"Biologic therapies in polyarticular juvenile idiopathic arthritis. Comparison of long-term safety data from the German BIKER registry","volume":"2","author":"Klein","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.012_bib29","doi-asserted-by":"crossref","first-page":"e1384","DOI":"10.1542\/peds.2013-0755","article-title":"Using registries to identify adverse events in rheumatic diseases abstract","volume":"132","author":"Lionetti","year":"2013","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.012_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","article-title":"Prevalence and incidence of juvenile idiopathic arthritis: a systematic review","volume":"81","author":"Thierry","year":"2014","journal-title":"Jt Bone Spine"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.012_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.07.012_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2021.07.012_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.07.012_bib35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.012_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"Horneff","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.012_bib37","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.012_bib38","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.012_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/rheumatology\/kex049","article-title":"Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis","volume":"57","author":"Lee","year":"2018","journal-title":"Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.012_bib40","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German Biologics in Pediatric Rheumatology Registry","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.012_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1744666X.2019.1550359","article-title":"Expert review of clinical immunology risks associated with use of TNF inhibitors in children with rheumatic diseases","volume":"15","author":"Marino","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.012_bib43","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","article-title":"Juvenile idiopathic arthritis and risk of cancer a nationwide cohort study","volume":"62","author":"Simard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.07.012_bib44","doi-asserted-by":"crossref","first-page":"e001055","DOI":"10.1136\/rmdopen-2019-001055","article-title":"Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies","volume":"5","author":"Horne","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2021.07.012_bib45","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2017-212613","article-title":"Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors","volume":"77","author":"Beukelman","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.07.012_bib46","first-page":"1113","article-title":"Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry","author":"Horneff","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 4","key":"10.1016\/j.rdc.2021.07.012_bib47","first-page":"399","article-title":"Digital pharmacovigilance and disease surveillance: combining traditional and big-data systems for better","volume":"214","author":"Salath\u00e9","year":"2016","journal-title":"Public Health"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21011066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21011066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:21:23Z","timestamp":1760181683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X21011066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0889857X21011066"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.012","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacosurveillance in Juvenile Idiopathic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}